Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. / Binding, Casper; Bjerring Olesen, Jonas; Abrahamsen, Bo; Staerk, Laila; Gislason, Gunnar; Nissen Bonde, Anders.

I: Journal of the American College of Cardiology, Bind 74, Nr. 17, 2019, s. 2150-2158.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Binding, C, Bjerring Olesen, J, Abrahamsen, B, Staerk, L, Gislason, G & Nissen Bonde, A 2019, 'Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants', Journal of the American College of Cardiology, bind 74, nr. 17, s. 2150-2158. https://doi.org/10.1016/j.jacc.2019.08.1025

APA

Binding, C., Bjerring Olesen, J., Abrahamsen, B., Staerk, L., Gislason, G., & Nissen Bonde, A. (2019). Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. Journal of the American College of Cardiology, 74(17), 2150-2158. https://doi.org/10.1016/j.jacc.2019.08.1025

Vancouver

Binding C, Bjerring Olesen J, Abrahamsen B, Staerk L, Gislason G, Nissen Bonde A. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. Journal of the American College of Cardiology. 2019;74(17):2150-2158. https://doi.org/10.1016/j.jacc.2019.08.1025

Author

Binding, Casper ; Bjerring Olesen, Jonas ; Abrahamsen, Bo ; Staerk, Laila ; Gislason, Gunnar ; Nissen Bonde, Anders. / Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants. I: Journal of the American College of Cardiology. 2019 ; Bind 74, Nr. 17. s. 2150-2158.

Bibtex

@article{a7d6842117d040c0ac62add41079dc2a,
title = "Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants",
abstract = "Background: Elderly patients in long-term treatment with vitamin K antagonists (VKAs) are at high risk of osteoporotic fractures compared with the background population. It has been speculated that the choice of oral anticoagulant (OAC) may affect the risk of osteoporotic fractures. Objectives: The risk of osteoporotic fractures was evaluated among patients with atrial fibrillation treated with VKA or direct oral anticoagulants (DOACs). Methods: Patients were identified using the Danish national registries. Patients were included only if they had no prior use of osteoporosis medication and they had undergone 180 days of OAC treatment. Outcomes were hip fracture, major osteoporotic fracture, any fracture, initiation of osteoporosis medication, and a combined endpoint. Results: Overall, 37,350 patients were included. The standardized absolute 2-year risk of any fracture was low among DOAC-treated patients (3.1%; 95% CI: 2.9% to 3.3%) and among VKA-treated patients (3.8%; 95% CI: 3.4% to 4.2%). DOAC was associated with a significantly lower relative risk of any fracture (hazard ratio [HR]: 0.85; 95% CI: 0.74 to 0.97), major osteoporotic fractures (HR: 0.85; 95% CI: 0.72 to 0.99), and initiating osteoporotic medication (HR: 0.82; 95% CI: 0.71 to 0.95). A combined endpoint showed that patients treated with DOAC had a significantly lower relative risk of experiencing any fracture or initiating osteoporosis medication (HR: 0.84; 95% CI: 0.76 to 0.93). Conclusions: In a nationwide population, the absolute risk of osteoporotic fractures was low among patients with atrial fibrillation on OAC, but DOAC was associated with a significantly lower risk of osteoporotic fractures compared with VKA.",
keywords = "atrial fibrillation, direct oral anticoagulants, osteoporosis, osteoporotic fracture, thromboprophylaxis, vitamin k antagonists",
author = "Casper Binding and {Bjerring Olesen}, Jonas and Bo Abrahamsen and Laila Staerk and Gunnar Gislason and {Nissen Bonde}, Anders",
year = "2019",
doi = "10.1016/j.jacc.2019.08.1025",
language = "English",
volume = "74",
pages = "2150--2158",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier",
number = "17",

}

RIS

TY - JOUR

T1 - Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants

AU - Binding, Casper

AU - Bjerring Olesen, Jonas

AU - Abrahamsen, Bo

AU - Staerk, Laila

AU - Gislason, Gunnar

AU - Nissen Bonde, Anders

PY - 2019

Y1 - 2019

N2 - Background: Elderly patients in long-term treatment with vitamin K antagonists (VKAs) are at high risk of osteoporotic fractures compared with the background population. It has been speculated that the choice of oral anticoagulant (OAC) may affect the risk of osteoporotic fractures. Objectives: The risk of osteoporotic fractures was evaluated among patients with atrial fibrillation treated with VKA or direct oral anticoagulants (DOACs). Methods: Patients were identified using the Danish national registries. Patients were included only if they had no prior use of osteoporosis medication and they had undergone 180 days of OAC treatment. Outcomes were hip fracture, major osteoporotic fracture, any fracture, initiation of osteoporosis medication, and a combined endpoint. Results: Overall, 37,350 patients were included. The standardized absolute 2-year risk of any fracture was low among DOAC-treated patients (3.1%; 95% CI: 2.9% to 3.3%) and among VKA-treated patients (3.8%; 95% CI: 3.4% to 4.2%). DOAC was associated with a significantly lower relative risk of any fracture (hazard ratio [HR]: 0.85; 95% CI: 0.74 to 0.97), major osteoporotic fractures (HR: 0.85; 95% CI: 0.72 to 0.99), and initiating osteoporotic medication (HR: 0.82; 95% CI: 0.71 to 0.95). A combined endpoint showed that patients treated with DOAC had a significantly lower relative risk of experiencing any fracture or initiating osteoporosis medication (HR: 0.84; 95% CI: 0.76 to 0.93). Conclusions: In a nationwide population, the absolute risk of osteoporotic fractures was low among patients with atrial fibrillation on OAC, but DOAC was associated with a significantly lower risk of osteoporotic fractures compared with VKA.

AB - Background: Elderly patients in long-term treatment with vitamin K antagonists (VKAs) are at high risk of osteoporotic fractures compared with the background population. It has been speculated that the choice of oral anticoagulant (OAC) may affect the risk of osteoporotic fractures. Objectives: The risk of osteoporotic fractures was evaluated among patients with atrial fibrillation treated with VKA or direct oral anticoagulants (DOACs). Methods: Patients were identified using the Danish national registries. Patients were included only if they had no prior use of osteoporosis medication and they had undergone 180 days of OAC treatment. Outcomes were hip fracture, major osteoporotic fracture, any fracture, initiation of osteoporosis medication, and a combined endpoint. Results: Overall, 37,350 patients were included. The standardized absolute 2-year risk of any fracture was low among DOAC-treated patients (3.1%; 95% CI: 2.9% to 3.3%) and among VKA-treated patients (3.8%; 95% CI: 3.4% to 4.2%). DOAC was associated with a significantly lower relative risk of any fracture (hazard ratio [HR]: 0.85; 95% CI: 0.74 to 0.97), major osteoporotic fractures (HR: 0.85; 95% CI: 0.72 to 0.99), and initiating osteoporotic medication (HR: 0.82; 95% CI: 0.71 to 0.95). A combined endpoint showed that patients treated with DOAC had a significantly lower relative risk of experiencing any fracture or initiating osteoporosis medication (HR: 0.84; 95% CI: 0.76 to 0.93). Conclusions: In a nationwide population, the absolute risk of osteoporotic fractures was low among patients with atrial fibrillation on OAC, but DOAC was associated with a significantly lower risk of osteoporotic fractures compared with VKA.

KW - atrial fibrillation

KW - direct oral anticoagulants

KW - osteoporosis

KW - osteoporotic fracture

KW - thromboprophylaxis

KW - vitamin k antagonists

U2 - 10.1016/j.jacc.2019.08.1025

DO - 10.1016/j.jacc.2019.08.1025

M3 - Journal article

C2 - 31648707

AN - SCOPUS:85072989716

VL - 74

SP - 2150

EP - 2158

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 17

ER -

ID: 238431486